You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
東誠藥業(002675.SZ)2021年度淨利潤預降59.31%-67.69%
格隆匯 02-04 14:52

格隆匯2月4日丨東誠藥業(002675.SZ)公佈,預計2021年度歸屬於上市公司股東的淨利潤1.35億元-1.7億元,同比下降59.31%-67.69%;扣除非經常性損益後的淨利潤1.1億元-1.4億元,同比下降64.43%-72.05%。業績變動原因如下:

(1)受國內外宏觀經濟、產業政策及產業週期等影響,結合公司實際經營情況等因素,根據證監會《會計監管風險提示第8號----商譽減值》相關要求,公司對報吿期內所有子公司的經營情況進行了全面估計,基於謹慎性原則,2021年預計對中泰生物製品有限公司70%股權資產組及煙台東誠大洋製藥有限公司資產組合計計提商譽減值準備約2.11億元,最終商譽減值準備計提金額將由公司聘請的具備證券期貨從業資格的評估機構及審計機構進行評估和審計後確定。

(2)目前APRINOIA Therapeutics Inc.的多款診療產品處於研發過程中,研發投入較大,對該公司的股權投資公司採用權益法核算。2021年因該投資導致公司計提投資收益為負數,進而拉低了公司當期淨利潤。

(3)原料藥產品銷售成本增加以及製劑產品受集採影響,導致經營毛利率下降。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account